Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
7.93
+0.57 (7.74%)
At close: Aug 7, 2026, 4:00 PM EDT
7.95
+0.02 (0.25%)
Pre-market: Aug 10, 2026, 7:45 AM EDT
Xeris Biopharma Holdings Revenue
Xeris Biopharma Holdings had revenue of $92.10M in the quarter ending June 30, 2026, with 28.74% growth. This brings the company's revenue in the last twelve months to $335.41M, up 36.33% year-over-year. In the year 2025, Xeris Biopharma Holdings had annual revenue of $291.85M with 43.72% growth.
Revenue (ttm)
$335.41M
Revenue Growth
+36.33%
P/S Ratio
4.31
Revenue / Employee
$771,067
Employees
435
Market Cap
1.45B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 291.85M | 88.78M | 43.72% |
| Dec 31, 2024 | 203.07M | 39.16M | 23.89% |
| Dec 31, 2023 | 163.91M | 53.67M | 48.68% |
| Dec 31, 2022 | 110.25M | 60.66M | 122.32% |
| Dec 31, 2021 | 49.59M | 29.16M | 142.67% |
| Dec 31, 2020 | 20.44M | 17.71M | 650.73% |
| Dec 31, 2019 | 2.72M | 299.00K | 12.34% |
| Dec 31, 2018 | 2.42M | 867.00K | 55.72% |
| Dec 31, 2017 | 1.56M | 481.00K | 44.74% |
| Dec 31, 2016 | 1.08M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Perrigo Company | 4.14B |
| Phibro Animal Health | 1.50B |
| Trulieve Cannabis | 1.14B |
| ANI Pharmaceuticals | 978.38M |
| Collegium Pharmaceutical | 808.21M |
| Pacira BioSciences | 746.16M |
| Alvotech | 562.04M |
| HUTCHMED (China) | 549.12M |
XERS News
- 3 days ago - Xeris Biopharma Holdings Earnings Call Transcript: Q2 2026 - Transcripts
- 3 days ago - Xeris Biopharma Holdings Earnings release: Q2 2026 - Filings
- 3 days ago - Xeris Biopharma Holdings Quarterly report: Q2 2026 - Filings
- 4 days ago - Xeris Biopharma tightens FY26 revnue view $385M-$390M, consensus $385.94M - TheFly
- 4 days ago - Xeris Biopharma Reports Second Quarter 2026 Financial Results - Business Wire
- 18 days ago - Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026 - Business Wire
- 5 weeks ago - CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
- 5 weeks ago - Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire